Skip to content

Study · Systematic review · 2025

16 results

Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews.

Hu X, Wang Y, Yang K, Li X

Endocrine16 Feb 2025

PMID39955702 (opens in a new tab)DOI10.1007/s12020-025-04179-x (opens in a new tab)PepBankPUB-39955702
Publisher pagePubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, pooled semaglutide trials showed an average weight loss of 11.71 kg.

    In plain wordsIn adults with obesity but no diabetes, semaglutide led to an average weight loss of 11.71 kg in pooled studies.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss in kg
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean weight change
    11.71 kg
    non-diabetic obesity

    Source sentences

    Summary
    revealing that semaglutide induced average weight loss 11.71 kg [-13.16, -10.26]
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  2. 02HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, pooled semaglutide trials showed a 12.79% weight reduction.

    In plain wordsIn adults with obesity but no diabetes, semaglutide led to a 12.79% weight reduction in pooled studies.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight reduction in percent
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean weight change
    12.79%
    non-diabetic obesity

    Source sentences

    Summary
    a 12.79% reduction [-14.4, -11.18].
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  3. 03HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, the rate of at least 5% weight loss increased significantly with semaglutide.

    In plain wordsIn adults with obesity but no diabetes, more people lost at least 5% of their weight on semaglutide in pooled studies.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss of at least 5%
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, ≥5, ≥10, ≥15, and ≥20% weight-loss rates significantly increased
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  4. 04HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, the rate of at least 10% weight loss increased significantly with semaglutide.

    In plain wordsIn adults with obesity but no diabetes, more people lost at least 10% of their weight on semaglutide in pooled studies.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss of at least 10%
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, ≥5, ≥10, ≥15, and ≥20% weight-loss rates significantly increased
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  5. 05HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, the rate of at least 15% weight loss increased significantly with semaglutide.

    In plain wordsIn adults with obesity but no diabetes, more people lost at least 15% of their weight on semaglutide in pooled studies.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss of at least 15%
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, ≥5, ≥10, ≥15, and ≥20% weight-loss rates significantly increased
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  6. 06HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, the rate of at least 20% weight loss increased significantly with semaglutide.

    In plain wordsIn adults with obesity but no diabetes, more people lost at least 20% of their weight on semaglutide in pooled studies.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss of at least 20%
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, ≥5, ≥10, ≥15, and ≥20% weight-loss rates significantly increased
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  7. 07HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, pooled semaglutide trials showed a waist reduction of 9.39 cm.

    In plain wordsIn adults with obesity but no diabetes, semaglutide reduced waist size by 9.39 cm in pooled studies.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Waist change
    9.39 cm
    non-diabetic obesity

    Source sentences

    Summary
    Semaglutide also reduced waist by 9.39 cm [-10, -8.79]
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  8. 08HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, pooled semaglutide trials showed a BMI reduction of 4.27 kg/m^2.

    In plain wordsIn adults with obesity but no diabetes, semaglutide lowered BMI by 4.27 kg/m^2 in pooled studies.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    BMI change
    4.27 kg/m^2
    non-diabetic obesity

    Source sentences

    Summary
    BMI by 4.27 kg/m^2 [-4.78, -3.75]
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  9. 09HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, pooled semaglutide trials showed a systolic blood pressure reduction of 4.78 mmHg.

    In plain wordsIn adults with obesity but no diabetes, semaglutide lowered systolic blood pressure by 4.78 mmHg in pooled studies.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    SBP change
    4.78 mmHg
    non-diabetic obesity

    Source sentences

    Summary
    SBP by 4.78 mmHg [-5.63, -3.93]
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  10. 10HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, pooled semaglutide trials showed a diastolic blood pressure reduction of 2.56 mmHg.

    In plain wordsIn adults with obesity but no diabetes, semaglutide lowered diastolic blood pressure by 2.56 mmHg in pooled studies.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiastolic blood pressure
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    DBP change
    2.56 mmHg
    non-diabetic obesity

    Source sentences

    Summary
    DBP by 2.56 mmHg [-3.96, -1.17]
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  11. 11HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, pooled semaglutide trials showed a lipid reduction of 3.2 mmol/l.

    In plain wordsIn adults with obesity but no diabetes, semaglutide lowered blood lipids by 3.2 mmol/l in pooled studies.

    Peptide
    Semaglutide
    Outcome
    DecreaseLipids
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Lipid change
    3.2 mmol/l
    non-diabetic obesity

    Source sentences

    Summary
    lipids by 3.2 mmol/l [-5.65, -0.75]
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  12. 12HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, pooled semaglutide trials showed a fasting blood glucose reduction of 5.46 mmol/l.

    In plain wordsIn adults with obesity but no diabetes, semaglutide lowered fasting blood glucose by 5.46 mmol/l in pooled studies.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting blood glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    FBG change
    5.46 mmol/l
    non-diabetic obesity

    Source sentences

    Summary
    FBG significantly dropped by 5.46 mmol/l [-8.99, -1.93]
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  13. 13HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, pooled semaglutide trials showed SF-36 scores improved by 1.7 points.

    In plain wordsIn adults with obesity but no diabetes, semaglutide improved quality-of-life scores by 1.7 points in pooled studies.

    Peptide
    Semaglutide
    Outcome
    IncreaseSF-36 quality-of-life score
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Measurements

    SF-36 change
    1.7 points
    non-diabetic obesity

    Source sentences

    Summary
    SF-36 scores improved by 1.7 points [0.78, 2.63]
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  14. 14HumanSystematic reviewSafety outcome

    In non-diabetic adults with obesity, nausea was a common adverse reaction to semaglutide in pooled trials.

    In plain wordsIn adults with obesity but no diabetes, nausea was a common side effect of semaglutide in pooled studies.

    Peptide
    Semaglutide
    Outcome
    IncreaseNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Relative risk
    2.59 RR
    nausea

    Source sentences

    Summary
    nausea [RR: 2.59], diarrhea [RR: 1.77], and constipation [RR: 2.07].
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  15. 15HumanSystematic reviewSafety outcome

    In non-diabetic adults with obesity, diarrhea was a common adverse reaction to semaglutide in pooled trials.

    In plain wordsIn adults with obesity but no diabetes, diarrhea was a common side effect of semaglutide in pooled studies.

    Peptide
    Semaglutide
    Outcome
    IncreaseDiarrhea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Relative risk
    1.77 RR
    diarrhea

    Source sentences

    Summary
    diarrhea [RR: 1.77], and constipation [RR: 2.07].
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.
  16. 16HumanSystematic reviewSafety outcome

    In non-diabetic adults with obesity, constipation was a common adverse reaction to semaglutide in pooled trials.

    In plain wordsIn adults with obesity but no diabetes, constipation was a common side effect of semaglutide in pooled studies.

    Peptide
    Semaglutide
    Outcome
    IncreaseConstipation
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Relative risk
    2.07 RR
    constipation

    Source sentences

    Summary
    constipation [RR: 2.07].
    1 context sentence
    Summary · context
    From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.